VITCLEAR study

A pharmacokinetic study: ranibizumab, aflibercept and the effect of vitrectomy. (VITCLEAR)

Justification of missing Results:

Sponsor Protocol Code:	VITCLEAR
EudraCT Number:	2012-005500-18
REC Number:	12/LO/1928
Investigational Drugs (IMPs):	Aflibercept (Eylea) Ranibizumab (Lucentis)
Indication:	Neovascular (wet) age-related macular degeneration (AMD).
Development Phase:	Phase IV
Study Begin (FPFV):	23/06/2014
Study End (LPLV):	15/07/2019
Co-sponsors:	King's College London and King's College Hospital NHS Foundation Trust.
Co-sponsor contact details:	King's Health Partners Clinical Trials Office Great Maze Pond, London SE1 9RT Tel: 020 7188 5732 Email: amy.holton@kcl.ac.uk
Chief Investigator:	Name: Tim Jackson King's College Hospital Denmark Hill London SE5 9RS Tel: 020 3299 1297 Email: t.jackson1@nhs.net

The VITCLEAR study was a pharmacokinetic and pharmacodynamic study to study ranibizumab and aflibercept after intravitreal injection. The study recruited 53 patients from 1 centre over 60 months. Primary outcome measures are currently still being analysed, with the COVID pandemic likely to impose further delay in the short to medium term due to the availability and shipping of drug assays